JAMESBURG, N.J., March 29 /PRNewswire/ -- Phytomedics Inc., a biopharmaceutical company merging health care and plant biotechnology to discover, develop, manufacture, and commercialize novel botanical therapeutics, announces the appointment of Aki von Roy to the position of chairman of its board of directors.
"We are extremely pleased to have a pharmaceutical executive of Aki's caliber join the Phytomedics board of directors as chairman," said Dr. Bertold Fridlender, President and CEO of Phytomedics. "With his breadth of executive and operational experience across the pharmaceutical industry, he is an extremely valuable addition to the Phytomedics team."
Mr. von Roy has spent a distinguished 41-year career in various capacities across the global pharmaceutical and biotechnology industries, including the position of President-Europe, Bristol-Myers Squibb (BMS), serving on both the pharmaceutical and corporate operating councils of the company. He has also served in executive management positions at Schering AG.
"I very much look forward to serving on the Phytomedics board of directors," said Mr. von Roy. "The company is leading a major paradigm shift in the development of novel pharmaceuticals through its FDA-approved botanical drug program. Phytomedics unique approach shows extreme promise in bringing novel drugs to market faster and less expensively, while at the same time appealing to the publics demand for natural healthcare alternatives within the prescriber-patient framework. I look forward to contributing to Phytomedics continuing future success."
A core area of Phytomedics pharmaceutical program are botanical drugs, as recently defined by the U.S. FDA (http://www.fda.gov/cder/Offices/ODE_V_BRT/botanicalDrug.htm). Phytomedics sees this as a unique pharmaceutical niche that allows for the development of heterogenous plant derived products as ethical drugs in the U.S., and do it for reduced costs and time frames in comparison to new chemical entities (NCEs) or biologics, while retaining strong drug market exclusivity and appealing to expanding consumer desires for natural healthcare alternatives.
About Phytomedics Inc.
Phytomedics Inc. (http://www.phytomedics.com) uses a broad and innovative proprietary technology platform to discover, develop, manufacture, and commercialize novel, multi-component and multi-functional botanical therapeutics. Through state-of- the-art, proprietary approaches, Phytomedics' botanical therapeutics program reconnects plants and human health at a new level of technological sophistication. The Company has produced a pipeline of lead compounds, several of which are in clinical development, some as far as Phase IIb. Founded by Professor Ilya Raskin, Ph.D., Phytomedics Inc. conducts most of its R&D at the Biotech Center of Rutgers University.
Phytomedics Inc.CONTACT: Ira S. Pastor, Vice President, Business Development ofPhytomedics Inc., Phone - +1-609-655-0715, Fax - +1-609-655-0552,pastor@phytomedics.com
Web site: http://www.phytomedics.com/
